NE BUSINESS BUREAU
KARKAPATLA, NOV 25
Biologicals firm Indian Immunologicals Ltd (IIL) on Wednesday said it will invest Rs 75 crore to commission a new viral antigen manufacturing facility in Phase III of Genome Valley, Karkapatla, Ranga Reddy District, Telangana to increase its capacity for supplying vaccines.
The new facility will be specially designed as a multi-product facility and cater to the need for viral vaccines in the pipeline, including for dengue, zika, and varicella, IIL said in a statement.
The senior management of the company, including Dr K Anand Kumar, Managing Director, and Dr Prasanna Deshpande, Deputy Managing Director were present during the ground-breaking of the upcoming viral antigen plant.
The company also plans to utilise the facility to manufacture COVID-19 vaccines post completion of its R&D with Griffith University, Australia, it added.
The company also inaugurated a new sterile filling facility that was commissioned last year to increase its capacity to supply lifesaving vaccines such as the Anti Rabies Vaccine (ARV) – Abhayrab, IIL said.
The Company also inaugurated a new Sterile Filling Facility that was commissioned last year at an additional investment of Rs 75 crores. This facility will increase IIL’s capacity to supply lifesaving vaccines such as the Anti Rabies Vaccine (ARV) – Abhayrab. As a part of the expansion plan, Indian Immunologicals Limited will add over 150 new positions, bringing its total staff strength close to 1,500. The new facility will boost the production capacity by over 35% and increase the supply capacity to key markets where rabies vaccine is critically needed.
“We are optimistic about the strategic investment as India is one of the key growth markets. As we mark as one of the major players on the pediatric and rabies vaccine, this expansion of our manufacturing facility is our commitment to securing a healthy and sustainable future,” IIL MD K Anand Kumar said.
“This facility has been specially designed to cater to the need for various viral vaccines and it will boost our manufacturing capacity by 35 percent. The new plant is expected to be ready for operation by October 2021,” IIL Deputy MD Prasanna Deshpande said.
IIL exports various human and animal vaccines to over 50 countries and currently employs around 1,300 people.
